Physician profile
Mohammed M Bakdash
NPI 1629066964
$136,350.97
in general payments reported to CMS, 2019-2025
29 companies · $966 in 2025
The $966 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60K · 2020: $31K · 2021: $23K · 2022: $17K · 2023: $2,349 · 2024: $2,576 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,232 · Travel and Lodging: $1,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,232.08 |
| Travel and Lodging | $1,658.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $55,794.36 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $34,920.67 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16,709.59 | 2019-2022 | |
| Mannkind Corporation | $11,575.37 | 2019-2025 | Afrezza |
| Lilly USA, LLC | $9,625.14 | 2019-2025 | Mounjaro, Zepbound, Lyumjev |
| Amgen INC. | $2,271.63 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $2,162.01 | 2021-2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $878.89 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kowa Pharmaceuticals America, INC. | $461.84 | 2021-2023 | Livalo, Seglentis |
| Artivion, INC. | $398.37 | 2022 | |
| Abbott Laboratories | $306.28 | 2022-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $293.20 | 2019-2025 | |
| Insulet Corporation | $167.01 | 2019-2024 | Omnipod |
| Cequr Corporation | $153.99 | 2022-2023 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $108.73 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $88.77 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $87.80 | 2023-2025 | Gvoke Hypopen |
| Corcept Therapeutics | $48.74 | 2025 | Korlym |
| Dexcom, INC. | $45.66 | 2021-2023 | Dexcom G6 Transmitter |
| Medtronic Minimed, INC. | $39.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $36.25 | 2022-2023 | |
| Beta Bionics, INC. | $31.35 | 2023-2024 | Ilet Bionic Pancreas |
| Acella Pharmaceuticals, LLC | $30.92 | 2025 | NP Thyroid 60 |
| Ascendis Pharma Endocrinology INC | $28.88 | 2025 | Yorvipath |
| Horizon Therapeutics Plc | $19.86 | 2021 | |
| Sequel Med Tech, LLC | $17.31 | 2025 | Twiist |
| Globus Medical, INC. | $16.54 | 2025 | Senza |
| Abbvie INC. | $16.12 | 2023 | Synthroid |
| Ultragenyx Pharmaceutical INC. | $15.76 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Bakdash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.